AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI

AbbVie Inc. (NYSE:ABBV) is simply a research-based biopharmaceutical institution that engages successful the probe and development, manufacturing, commercializing, and merchantability of medicines and therapies worldwide.

On May 15, Evercore ISI somewhat trimmed its terms people connected AbbVie Inc. (NYSE:ABBV) from $236 to $235, but maintained its ‘Outperform’ standing connected the shares. The lowered target, which inactive indicates an upside of implicit 12% from the existent terms level, comes aft the institution reported mixed results for its Q1 past month.

AbbVie Inc. (NYSE:ABBV) reported adjusted net of $2.65 per stock for the archetypal quarter, falling somewhat beneath estimates by $0.02. However, its gross grew by implicit 12% YoY to $15 cardinal and exceeded estimates by $280 million. The beardown gross maturation was driven by the request for the company’s newer immunology drugs Skyrizi and Rinvoq, arsenic ‌it continues to determination beyond erstwhile top-selling attraction Humira.

AbbVie Inc. (NYSE:ABBV) besides raised its full-year 2026 adjusted EPS guidance to ⁠a scope ​of $14.08 to $14.28, from $13.96 to $14.16 previously. Moreover, the institution present expects full nett revenues of astir $67.3 cardinal for the year, up from its anterior forecast of astir $67 billion.

While we admit the imaginable of ABBV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Blue Chip Dividend Stocks to Buy Now and 11 Best Rising Dividend Stocks to Buy Right Now

Disclosure: None. Follow Insider Monkey connected Google News.